Abstract
Quantitative MRI quantifies tissue microstructural properties and supports the characterization of cerebral tissue damages. With an MPM protocol, 4 parameter maps are constructed: MTsat, PD, R1 and R2*, reflecting tissue physical properties associated with iron and myelin contents. Thus, qMRI is a good candidate for in vivo monitoring of cerebral damage and repair mechanisms related to MS. Here, we used qMRI to investigate the longitudinal microstructural changes in MS brain.
Seventeen MS patients (age 25-65, 11 RRMS) were scanned on a 3T MRI, in two sessions separated with a median of 30 months, and the parameters evolution was evaluated within several tissue classes: NAWM, NACGM and NADGM, as well as focal WM lesions. An individual annual rate of change for each qMRI parameter was computed, and its correlation to clinical status was evaluated. For WM plaques, three areas were defined, and a GLMM tested the effect of area, time points, and their interaction on each median qMRI parameter value.
Patients with a better clinical evolution, i.e., clinically stable or improving state, showed positive annual rate of change in MTsat and R2* within NAWM and NACGM, suggesting repair mechanisms in terms of increased myelin content and/or axonal density as well as edema/inflammation resorption. When examining WM lesions, qMRI parameters within surrounding NAWM showed microstructural modifications, even before any focal lesion is visible on conventional FLAIR MRI.
The results illustrate the benefit of multiple qMRI data in monitoring subtle changes within normal appearing brain tissues and plaque dynamics in relation with tissue repair or disease progression.
Key points
Patients with a better clinical evolution showed microstructural improvement in term of MTsat and R2* increase in their normal appearing tissue, suggesting repair mechanisms.
Using qMRI allows to detect modifications in tissue microstructure in normal appearing tissues surrounding lesions several months before they are visible on conventional MRI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The main contributors are supported by the Fonds de la Recherche Scientifique (F.R.S-FNRS Belgium)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the University of Liege Hospital gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data availability The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Conflict interests None.
This version of the manuscript was based on the Reviewer's comments after submission to 'Brain and Behavior' The abstract and introduction were modified to better highlight the scientific interest of the method. Table 2 was added to the main text (initially in Supplementary material).
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ARoC
- Annual Rate of Change
- BPF
- Brain Parenchymal Fraction
- CDP
- Confirmed Disability Progression
- cMRI
- Conventional Magnetic Resonance Imaging
- CNS
- Central Nervous System
- GMF
- Grey Matter Fraction
- GLMM
- General Linear Mixed Model
- LF
- Lesion Fraction
- MPM
- Multi-Parameter Mapping
- MRI
- Magnetic Resonance Imaging
- MS
- Multiple Sclerosis
- MT
- Magnetization Transfer
- MTR
- Magnetization Transfer Ratio
- MTsat
- Saturated Magnetization Transfer
- NABT
- Normal Appearing Brain Tissue
- NACGM
- Normal Appearing Cortical Grey Matter
- NADGM
- Normal Appearing Deep Grey matter
- NAWM
- Normal Appearing White Matter
- NEDA-3
- No Evidence of Disease Activity
- RRMS
- Relapsing-Remitting Multiple Sclerosis
- PD
- Proton Density
- PMS
- Progressive Multiple Sclerosis
- qMRI
- Quantitative Magnetic Resonance Imaging
- R1
- Longitudinal Relaxation Rate (1/T1)
- R2*
- Transverse Relaxation Rate (1/T2*)
- TIV
- Total Intracranial Volume
- TPM
- Tissue Probability Map
- US
- Unified Segmentation
- USwL
- Unified Segmentation with Lesion
